Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Currently undergoing cervical, thoracic, or lumbar discectomy; corpectomy, laminectomy, lateral or interbody fusion, including both anterior and posterior approaches (not including minimally invasive procedures; arterial reconstruction; peripheral artery bypass (PAB) grafting; or arteriovenous (AV) vascular access procedures~* History of surgery with high likelihood of exposure to bovine thrombin within the past 3 years. Prior surgery must have been 1 of the following open procedures: open procedures involving the spine or cranium, PAB grafting, AV vascular access procedures, autologous skin grafting, or other surgical procedure accompanied by documented treatment with bovine thrombin~* Age of 18 years or younger at time of informed consent~* If female and of child-bearing potential: Negative pregnancy test result within 14 days prior to treatment~* Use of a medically accepted form of contraception from the time of informed consent to completion of all follow-up study visits, if sexually active male or a sexually active female of childbearing potential~* Signed IRB/independent ethics committee-approved informed consent document~Exclusion Criteria:~* Currently undergoing procedures requiring cardiopulmonary bypass or involving the aortic arch~* Known hypersensitivity to rThrombin or any of its components~* Presence of medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures~* Breastfeeding~* Receipt of treatment with any experimental agent within 30 days of study enrollment or treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): rThrombin

Based on this trial design, predict the completion outcome and termination type (if applicable).